[REVISION HISTORY]

EASD diabetes congress in Milan

Updated 6 times since CLSTR started tracking revisions of this situation.

What changed

2026-09-30 19:55 UTC → 2026-10-04 03:23 UTC · added ~~removed~~

The 62nd Congress of the European Association for the Study of Diabetes (EASD) in Milan highlighted significant advancements in diabetes management, screening, and therapeutic guidelines. Clinical discussions centered on the efficacy of semaglutide, which has received a recommendation 1A in the ESC 2026 Guidelines for patients with diabetes and kidney disease. Data presented at the congress confirmed semaglutide reduces major cardiovascular events by 26%, non-fatal strokes by 39%, and composite renal risk by 24%, while also improving functional capacity by 13%. Technological innovation ~~was~~ remains a major theme, particularly regarding non-invasive screening. An AI model developed by Thymia and RMIT University can identify signs of type 2 diabetes by analyzing vocal patterns, such as hoarseness or irregular breath control, in as little as 20 seconds. central theme. While ~~this offers rapid screening potential, researchers previously noted a 47% false positive rate during validation. Regarding~~ previous discussions focused on AI-driven vocal pattern analysis for screening, the 2026 congress has expanded into automated insulin delivery. Companies SiBionics and PharmaSens are presenting the “niia signature,” an investigational wearable patch designed to integrate continuous glucose monitoring (CGM), insulin delivery, and an automated glucose control algorithm into a ~~Dexcom report indicated that 89% of healthcare professionals believe CGM aids in assessing treatment adherence for type 2 diabetes. In terms of~~ single unit. Research is also exploring multimodal sensing, such as continuous ketone monitoring, to improve metabolic control. Public outreach has also increased, with “off-congress” events moving research into museums and public squares through free glucose screenings and citizen science workshops. Regarding pregnancy safety, a meta-analysis of over 43,000 women found no significant association between GLP-1 receptor agonist exposure and risks such as preterm birth, fetal death, or ~~pre-eclampsia. However,~~ pre-eclampsia, though researchers noted a 31% frequency of early pregnancy loss among exposed ~~women, though they~~ women and cautioned that data limitations make definitive conclusions difficult. On a policy level, the European Commission launched the first EU Screening Week to encourage early detection of cardiovascular risk ~~factors, including blood pressure and cholesterol, to mitigate the economic and health burdens of heart disease.~~ factors.

Versions

Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.